Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS-SPAF)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Moonki | - |
dc.contributor.author | Byeon, Kyeongmin | - |
dc.contributor.author | Kang, Ki-Woon | - |
dc.contributor.author | Lee, Wang-Soo | - |
dc.contributor.author | Kim, Sang Wook | - |
dc.contributor.author | Park, Yae Min | - |
dc.contributor.author | Hwang, You Mi | - |
dc.contributor.author | Lee, Sung Ho | - |
dc.contributor.author | Jin, Eun-Sun | - |
dc.contributor.author | Roh, Seung-Young | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Ahn, Jinhee | - |
dc.contributor.author | Lee, So-Ryoung | - |
dc.contributor.author | Choi, Eue-Keun | - |
dc.contributor.author | Ahn, Min-Soo | - |
dc.contributor.author | Lee, Eun Mi | - |
dc.contributor.author | Park, Hwan-Cheol | - |
dc.contributor.author | Lee, Ki Hong | - |
dc.contributor.author | Kim, Min | - |
dc.contributor.author | Choi, Joon Hyouk | - |
dc.contributor.author | Ko, Jum Suk | - |
dc.contributor.author | Kim, Jin Bae | - |
dc.contributor.author | Kim, Changsoo | - |
dc.contributor.author | Lip, Gregory Y. H. | - |
dc.contributor.author | Shin, Seung Yong | - |
dc.date.accessioned | 2024-01-18T02:01:02Z | - |
dc.date.available | 2024-01-18T02:01:02Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 1880-4276 | - |
dc.identifier.issn | 1883-2148 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/71008 | - |
dc.description.abstract | BackgroundThe balance of stroke risk reduction and potential bleeding risk associated with antithrombotic treatment (ATT) remains unclear in atrial fibrillation (AF) at non-gender CHA(2)DS(2)-VASc scores 0-1. A net clinical benefit (NCB) analysis of ATT may guide stroke prevention strategies in AF with non-gender CHA(2)DS(2)-VASc scores 0-1. MethodsThis multi-center cohort study evaluated the clinical outcomes of treatment with a single antiplatelet (SAPT), vitamin K antagonist (VKA), and non-VKA oral anticoagulant (NOAC) in non-gender CHA(2)DS(2)-VASc score 0-1 and further stratified by biomarker-based ABCD score (Age [>= 60 years], B-type natriuretic peptide [BNP] or N-terminal pro-BNP [>= 300 pg/mL], creatinine clearance [<50 mL/min], and dimension of the left atrium [>= 45 mm]). The primary outcome was the NCB of ATT, including composite thrombotic events (ischemic stroke, systemic embolism, and myocardial infarction) and major bleeding events. ResultsWe included 2465 patients (age 56.2 +/- 9.5 years; female 27.0%) followed-up for 4.0 +/- 2.8 years, of whom 661 (26.8%) were treated with SAPT; 423 (17.2%) with VKA; and 1040 (42.2%) with NOAC. With detailed risk stratification using the ABCD score, NOAC showed a significant positive NCB compared with the other ATTs (SAPT vs. NOAC, NCB 2.01, 95% confidence interval [CI] 0.37-4.66; VKA vs. NOAC, NCB 2.38, 95% CI 0.56-5.40) in ABCD score >= 1. ATT failed to show a positive NCB in patients with truly low stroke risk (ABCD score = 0). ConclusionsIn the Korean AF cohort at non-gender CHA(2)DS(2)-VASc scores 0-1, NOAC showed significant NCB advantages over VKA or SAPT with ABCD score >= 1. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Net clinical benefit of oral anticoagulants in Korean atrial fibrillation patients with low to intermediate stroke risk: A report from the Clinical Survey on Stroke Prevention in patients with Atrial Fibrillation (CS-SPAF) | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/joa3.12840 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ARRHYTHMIA, v.39, no.3, pp 376 - 387 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000946337800001 | - |
dc.identifier.scopusid | 2-s2.0-85150617388 | - |
dc.citation.endPage | 387 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 376 | - |
dc.citation.title | JOURNAL OF ARRHYTHMIA | - |
dc.citation.volume | 39 | - |
dc.type.docType | Article; Early Access | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | ABCD score | - |
dc.subject.keywordAuthor | antithrombotic treatment | - |
dc.subject.keywordAuthor | atrial fibrillation | - |
dc.subject.keywordAuthor | net clinical benefit | - |
dc.subject.keywordAuthor | non-vitamin K antagonist oral anticoagulant | - |
dc.subject.keywordPlus | MODELING ANALYSIS | - |
dc.subject.keywordPlus | APIXABAN | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | THROMBOEMBOLISM | - |
dc.subject.keywordPlus | STRATIFICATION | - |
dc.subject.keywordPlus | RIVAROXABAN | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | POPULATION | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.